Loading...

Expanding Into $18 Billion Diagnostics Market Will Boost Prospects Despite Potential Risks

Published
11 Feb 25
Updated
01 May 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
29.4%
7D
-3.9%

Author's Valuation

NOK 6718.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 01 May 25

Fair value Decreased 1.09%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 3.94%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Decreased 2.73%

AnalystConsensusTarget has increased revenue growth from 26.1% to 29.5%, decreased profit margin from 15.9% to 11.0% and increased future PE multiple from 24.6x to 33.5x.